COMMUNIQUÉS West-GlobeNewswire

PolTREG receives CGMP certification to produce cell therapies at its state-of-the-art manufacturing site in Poland
11/03/2024
Gdańsk, Poland – 11 March 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG) , a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases, today announces it has received CGMP [...]
PHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market
11/03/2024
Lyon (France) and Cambridge (MA, US), March 11, 2024, at 07:00am CET – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial [...]
PHAXIAM Therapeutics annonce la réalisation du retrait volontaire de ses « American Depository Shares » du Nasdaq Stock Market
11/03/2024
Lyon (France) et Cambridge (MA, US), le 11 mars 2024, à 7h00 CET - PHAXIAM Therapeutics (Nasdaq & Euronext : PHXM), société biopharmaceutique qui développe des traitements innovants contre les infections [...]
Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
11/03/2024
New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis Late-breaking data at AAD show sustained off-drug improvements of AD signs and symptoms with [...]
Communiqué de presse : De nouveaux résultats de phase II relatifs à l’amlitelimab confortent son potentiel de meilleur médicament de sa catégorie en termes de maintien de la réponse dans le traitement de la dermatite atopique
11/03/2024
De nouveaux résultats de phase II relatifs à l’amlitelimab confortent son potentiel de meilleur médicament de sa catégorie en termes de maintien de la réponse dans le traitement de la dermatite atopique Des données de [...]
United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)
11/03/2024
NEW YORK, March 10, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that U.S. FDA supports an accelerated [...]
Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting
10/03/2024
Investigational roflumilast cream 0.05% met the primary endpoint and all secondary endpoints, showing significant improvement across multiple efficacy endpoints as early as Week 1 39.4% of children treated with [...]
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
10/03/2024
MoonLake announces significant improvements with Nanobody ® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day Positive 24-week data from the ARGO trial of [...]
New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction
09/03/2024
Findings show that seborrheic dermatitis is a unique inflammatory skin disease with its own molecular signature Suggests skin barrier disruption in seborrheic dermatitis is distinct with its own disease-specific pattern [...]
Alumis Presents Positive Data from Phase 2 Clinical Trial of ESK-001, an Oral Allosteric TYK2 Inhibitor for the Treatment of Plaque Psoriasis, at AAD Annual Meeting
09/03/2024
– STRIDE Phase 2 primary endpoint of PASI 75 and key secondary endpoints met at all clinically relevant doses tested; sustained maximal target inhibition safely achieved at top dose – – Open label extension (OLE) study [...]
Samsung Bioepis Presents Two Abstracts for Its Immunology Portfolio at the 2024 American Academy of Dermatology (AAD) Annual Meeting
09/03/2024
Interchangeability study for HADLIMA (adalimumab-bwwd) was conducted in accordance with the FDA’s Guidance for Industry; primary pharmacokinetics (PK) endpoints as well as efficacy, safety and immunogenicity profiles [...]
Ultimovacs ASA: Mandatory notification of trades by primary insider
09/03/2024
Oslo, 9 March 2024: Langøya Invest AS, a closely related party of Ketil Fjerdingen, a board member and primary insider in Ultimovacs ASA, sold on 8 March 2024, 400,000 shares in the company at an average price of NOK 7. [...]
Aesthetic Medical International Holdings Group Ltd. Announces Receipt of a Letter of Expected Delisting Determination From Nasdaq Staff and Intention to Request a Hearing before the Nasdaq Hearings Panel
08/03/2024
SHENZHEN, China, March 08, 2024 (GLOBE NEWSWIRE) -- Aesthetic Medical International Holdings Group Limited (Nasdaq: AIH) (the “Company” or “AIH”), a leading provider of aesthetic medical services in China, today [...]
Confluent Appoints Sandy Stojkovski and Brian Yoor to its Board of Directors
08/03/2024
SCOTTSDALE, Ariz., March 08, 2024 (GLOBE NEWSWIRE) -- Confluent Medical Technologies, a leading materials science platform that supports the design, development and manufacturing of life saving implants, today announced [...]
Ultimovacs ASA: Mandatory notification of trades by primary insider
08/03/2024
Oslo, 8 March 2024: CGS Holding AS, a closely related party of Leiv Askvig, a board member and primary insider in Ultimovacs ASA, has today sold 140,000 shares in the company at an average price of NOK 7.2507 per share [...]
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08/03/2024
CAMBRIDGE, Mass., March 08, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with [...]
PharmAla Announces Voting Results of Annual General and Special Meeting of Shareholders and Provides Corporate Update
08/03/2024
VANCOUVER, British Columbia, March 08, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and [...]
Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates
08/03/2024
JERUSALEM, March 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, today reported financial results and key business [...]
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08/03/2024
REDWOOD CITY, Calif., March 08, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, [...]

Pages